Novozymes A/S Stock Forecast, Price & News

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Novozymes A/S in the last year. There are currently 2 sell ratings, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Novozymes A/S stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVZMY, but not buy additional shares or sell existing shares.
View analyst ratings for Novozymes A/S or view top-rated stocks.

Wall Street analysts have given Novozymes A/S a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Novozymes A/S wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Novozymes A/S saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 14,400 shares, a decline of 30.8% from the March 15th total of 20,800 shares. Based on an average daily volume of 17,900 shares, the short-interest ratio is presently 0.8 days.
View Novozymes A/S's Short Interest.

Novozymes A/S is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for Novozymes A/S.

Novozymes A/S (OTCMKTS:NVZMY) issued its earnings results on Tuesday, February, 2nd. The biotechnology company reported $0.37 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.42 by $0.05. The biotechnology company earned $552.16 million during the quarter, compared to analyst estimates of $550.66 million. Novozymes A/S had a trailing twelve-month return on equity of 28.09% and a net margin of 21.63%.
View Novozymes A/S's earnings history.

Novozymes A/S's stock was trading at $45.0314 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NVZMY stock has increased by 51.8% and is now trading at $68.35.
View which stocks have been most impacted by COVID-19.

Novozymes A/S announced a dividend on Monday, March 1st. Stockholders of record on Monday, March 15th will be paid a dividend of $0.8492 per share on Wednesday, March 31st. This represents a yield of 1.38%. The ex-dividend date of this dividend is Friday, March 12th.
View Novozymes A/S's dividend history.

Novozymes A/S pays an annual dividend of $0.56 per share and currently has a dividend yield of 0.83%. The dividend payout ratio of Novozymes A/S is 33.94%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Novozymes A/S will have a dividend payout ratio of 32.37% next year. This indicates that Novozymes A/S will be able to sustain or increase its dividend.
View Novozymes A/S's dividend history.

Some companies that are related to Novozymes A/S include BioNTech (BNTX), Biogen (BIIB), Seagen (SGEN), Bio-Techne (TECH), Novavax (NVAX), argenx (ARGX), Repligen (RGEN), QIAGEN (QGEN), CRISPR Therapeutics (CRSP), Neurocrine Biosciences (NBIX), Fate Therapeutics (FATE), Acceleron Pharma (XLRN), Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI) and Twist Bioscience (TWST).
View all of NVZMY's competitors.

Novozymes A/S trades on the OTCMKTS under the ticker symbol "NVZMY."

Shares of NVZMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NVZMY stock can currently be purchased for approximately $68.35.

Novozymes A/S has a market capitalization of $15.81 billion and generates $2.16 billion in revenue each year. The biotechnology company earns $472.79 million in net income (profit) each year or $1.65 on an earnings per share basis.

Novozymes A/S employs 5,903 workers across the globe.

The following companies are subsidiares of Novozymes A/S: Allopartis, Beta Renewables S.p.A., Delta Biotechnology, Earth BioSciences, Grundejerforeningen Hallas Park, Grundejerforeningen Smørmosen, Iogen Bio-Products, MagnaBioAnalytics LLC, Microbiogen PTY Ltd., Natural Industries, Novozymes (China) Biotechnology Co. Ltd., Novozymes (China) Investment Co. Ltd., Novozymes (Shenyang) Biologicals Co. Ltd., Novozymes (Thailand) Limited, Novozymes Australia Pty. Ltd., Novozymes Belgium BVBA, Novozymes BioAg A/S, Novozymes BioAg Inc., Novozymes BioAg Limited, Novozymes BioAg Productos Para Agricultura Ltda., Novozymes BioAg S.A., Novozymes Bioindustrial A/S, Novozymes Bioindustrial China A/S, Novozymes Biologicals Inc., Novozymes Biopharma DK A/S, Novozymes Blair Inc., Novozymes Canada Limited, Novozymes Deutschland GmbH, Novozymes Enzim Dis Ticaret Ltd., Novozymes France S.A.S, Novozymes Hong Kong Ltd., Novozymes Inc., Novozymes Italia S.r.l., Novozymes Japan Ltd., Novozymes Korea Limited, Novozymes Latin America Ltda., Novozymes Malaysia Sdn. Bhd., Novozymes Mexicana S.A. de C.V., Novozymes Mexico S.A. de C.V., Novozymes Nederland B.V., Novozymes North America Inc., Novozymes RUS LLC, Novozymes Singapore Pte. Ltd., Novozymes South Africa (Pty) Ltd., Novozymes South Asia Pvt. Ltd., Novozymes Spain S.A., Novozymes Sweden AB, Novozymes Switzerland AG, Novozymes Switzerland Holding AG, Novozymes UK Ltd, Novozymes US Inc., OrganoBalance GmbH, Pacific Vet Group-USA, Philom Bios, PrecisionBiotics Group Limited, Qingdao Huayuan Fine Bio-Products, Suzhou Hongda Enzyme Co. Ltd., Sybron Biochemicals, TJ Technologies, and Turfal Indústria e Comércio de Produtos Agrônomicos e Biológicos.

Novozymes A/S was founded in 2000.

The official website for Novozymes A/S is www.novozymes.com.

Novozymes A/S is headquartered at Krogshoejvej 36, Bagsvaerd G7, 2880.

Novozymes A/S's mailing address is Krogshoejvej 36, Bagsvaerd G7, 2880. The biotechnology company can be reached via phone at 45-4446-0000 or via email at [email protected]